S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
NASDAQ:KRYS

Krystal Biotech - KRYS Stock Forecast, Price & News

$84.22
+0.24 (+0.29%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$82.63
$85.21
50-Day Range
$71.03
$84.27
52-Week Range
$47.67
$85.65
Volume
97,870 shs
Average Volume
199,046 shs
Market Capitalization
$2.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$106.75

Krystal Biotech MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
26.8% Upside
$106.75 Price Target
Short Interest
Bearish
5.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
0.84mentions of Krystal Biotech in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$5.85 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.36) to ($4.84) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

275th out of 1,049 stocks

Biological Products, Except Diagnostic Industry

48th out of 170 stocks


KRYS stock logo

About Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

KRYS Stock News Headlines

Krystal Biotech, Inc. (NASDAQ:KRYS) Short Interest Update
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Krystal Biotech’s stock is down on delayed PDUFA date
BofA Securities: The most promising biotech stocks in 2023
12 Best Small-Cap Healthcare Stocks To Buy Now
2 Risky Stocks That Could Soar in 2023
Vertex: High Growth For Years Ahead
Krystal Biotech Needs to Feed the Goldfish in 2023
Recap: Krystal Biotech Q3 Earnings
See More Headlines
Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

KRYS Company Calendar

Last Earnings
11/07/2022
Today
1/29/2023
Next Earnings (Estimated)
2/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KRYS
Fax
N/A
Employees
119
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$106.75
High Stock Price Forecast
$133.00
Low Stock Price Forecast
$74.00
Forecasted Upside/Downside
+26.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-69,570,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$26.69 per share

Miscellaneous

Free Float
21,165,000
Market Cap
$2.17 billion
Optionable
Not Optionable
Beta
0.84

Key Executives

  • Mr. Krish S. Krishnan M.B.A. (Age 58)
    M.S., Founder, Chairman, Pres & CEO
    Comp: $1.01M
  • Ms. Suma M. KrishnanMs. Suma M. Krishnan (Age 58)
    Founder, COO, Pres of R&D and Director
    Comp: $708.56k
  • Ms. Kathryn A. Romano (Age 41)
    Exec. VP & Chief Accounting Officer
    Comp: $452.43k
  • Dr. Andreas C. Orth (Age 53)
    Exec. VP & Chief Commercial Officer
    Comp: $549.17k
  • Ms. Gloria Lin
    Accounting Mang.
  • Mr. Ram Kamineni
    Sr. VP of CMC & Technical Operations
  • Ms. Meg Dodge
    VP of Investor Relations & Corp. Communications
  • Mr. David Glynn
    Gen. Counsel, Commercial & Compliance
  • Mr. John Karakkal
    VP of North American Sales & Marketing
  • Ms. Katherine Tuminello
    HR & Office Mang.













KRYS Stock - Frequently Asked Questions

Should I buy or sell Krystal Biotech stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KRYS shares.
View KRYS analyst ratings
or view top-rated stocks.

What is Krystal Biotech's stock price forecast for 2023?

3 brokers have issued 12-month price targets for Krystal Biotech's shares. Their KRYS share price forecasts range from $74.00 to $133.00. On average, they anticipate the company's stock price to reach $106.75 in the next twelve months. This suggests a possible upside of 26.8% from the stock's current price.
View analysts price targets for KRYS
or view top-rated stocks among Wall Street analysts.

How have KRYS shares performed in 2023?

Krystal Biotech's stock was trading at $79.22 on January 1st, 2023. Since then, KRYS shares have increased by 6.3% and is now trading at $84.22.
View the best growth stocks for 2023 here
.

Are investors shorting Krystal Biotech?

Krystal Biotech saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 1,130,000 shares, an increase of 14.4% from the December 31st total of 988,100 shares. Based on an average trading volume of 174,600 shares, the days-to-cover ratio is currently 6.5 days. Currently, 5.4% of the shares of the company are short sold.
View Krystal Biotech's Short Interest
.

When is Krystal Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our KRYS earnings forecast
.

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) announced its quarterly earnings results on Monday, November, 7th. The company reported ($1.17) EPS for the quarter, topping analysts' consensus estimates of ($1.23) by $0.06.

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO.

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by a variety of institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.18%) and Harbor Capital Advisors Inc. (0.03%). Insiders that own company stock include Krish S Krishnan and Suma Krishnan.
View institutional ownership trends
.

How do I buy shares of Krystal Biotech?

Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $84.22.

How much money does Krystal Biotech make?

Krystal Biotech (NASDAQ:KRYS) has a market capitalization of $2.17 billion. The company earns $-69,570,000.00 in net income (profit) each year or ($5.20) on an earnings per share basis.

How many employees does Krystal Biotech have?

The company employs 119 workers across the globe.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The official website for the company is www.krystalbio.com. The company can be reached via phone at (412) 586-5830 or via email at arr@lifesciadvisors.com.

This page (NASDAQ:KRYS) was last updated on 1/29/2023 by MarketBeat.com Staff